false
zh-CN,zh-TW,en,fr,de,ja,ko,pt,es,th,vi
Catalog
2023 ACMG Annual Clinical Genetics Meeting Digital ...
Designing an Untargeted Metabolomics Assay to Dete ...
Designing an Untargeted Metabolomics Assay to Detect Biomarkers for Inborn Errors of Metabolism in the Clinical Laboratory
Back to course
Pdf Summary
This document discusses the development of an untargeted metabolomics assay for the detection of biomarkers related to inborn errors of metabolism (IEMs) in the clinical laboratory. IEMs are inherited disorders that affect metabolism and can be diagnosed through the evaluation of metabolites. The untargeted approach allows for the analysis of multiple metabolites simultaneously, potentially uncovering new biomarkers and aiding in the characterization of novel conditions.<br /><br />The study found that 88% of the reference standards were detected by the assay. The hydrophilic interaction liquid chromatography (HILIC) column detected 71% of the standards, while the reverse phase (RP) column detected 33%. Both columns resolved 17% of the standards. In the presence of plasma, 4% of the standards were suppressed to levels below the limit of detection.<br /><br />Internal standard retention time stability was assessed, and the assay demonstrated good stability with low variation between batches. The sample preparation involved analyzing a mixture of 165 reference standards from various compound classes common to IEMs. Chromatographic resolution for each standard was determined by comparison to a reference spectral database.<br /><br />The assay utilized a dual-liquid chromatography quadrupole time-of-flight mass spectrometry method. The X500B QTOF system operated in data-independent acquisition mode. Future directions for the research include biomarker discovery in patient cohorts and the characterization of different sample types.<br /><br />In conclusion, the untargeted metabolomics assay demonstrated the ability to detect known biomarkers for IEMs. It has the potential to streamline the diagnosis of IEMs and improve patient outcomes by leveraging the metabolome for biomarker discovery and understanding IEM mechanisms for novel treatment strategies.
Asset Subtitle
Presenting Author - Rachel Wurth, MS; Co-Author - Coleman Turgeon, MS; Co-Author - Zinandré Stander, PhD; Co-Author - Dimitar K. Gavrilov, MD, PhD; Co-Author - Patricia L. Hall, PhD; Co-Author - Dietrich Matern, MD, PhD, FACMG; Co-Author - Matthew Schultz, PhD; Co-Author - Silvia Tortorelli, MD,PhD; Co-Author - Devin Oglesbee, PhD;
Meta Tag
Biochemical genetics
Differentiation
Lysosomal Diseases
Metabolic Disorder
Co-Author
Coleman Turgeon, MS
Co-Author
Zinandré Stander, PhD
Co-Author
Dimitar K. Gavrilov, MD, PhD
Co-Author
Patricia L. Hall, PhD
Co-Author
Dietrich Matern, MD, PhD, FACMG
Co-Author
Matthew Schultz, PhD
Co-Author
Silvia Tortorelli, MD,PhD
Co-Author
Devin Oglesbee, PhD
Presenting Author
Rachel Wurth, MS
Keywords
untargeted metabolomics assay
biomarkers
inborn errors of metabolism
clinical laboratory
metabolites
diagnosis
hydrophilic interaction liquid chromatography
reverse phase column
plasma
internal standard retention time stability
© 2025 American College of Medical Genetics and Genomics. All rights reserved.
×